BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 36623445)

  • 1. CRISPR screening reveals gleason score and castration resistance related oncodriver ring finger protein 19 A (RNF19A) in prostate cancer.
    Zhang N; Huang D; Ruan X; Ng AT; Tsu JH; Jiang G; Huang J; Zhan Y; Na R
    Drug Resist Updat; 2023 Mar; 67():100912. PubMed ID: 36623445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CRISPR genome-wide screening identifies PAK1 as a critical driver of ARSI cross-resistance in prostate cancer progression.
    Chen H; Dong K; Ding J; Xia J; Qu F; Lan F; Liao H; Qian Y; Huang J; Xu Z; Gu Z; Shi B; Yu M; Cui X; Yu Y
    Cancer Lett; 2024 Apr; 587():216725. PubMed ID: 38364963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
    Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK
    Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ring finger protein 19A is overexpressed in non-small cell lung cancer and mediates p53 ubiquitin-degradation to promote cancer growth.
    Cheng Y; Hu Y; Wang H; Zhao Z; Jiang X; Zhang Y; Zhang J; Tong Y; Qiu X
    J Cell Mol Med; 2021 Aug; 25(16):7796-7808. PubMed ID: 34184814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A hormone-dependent feedback-loop controls androgen receptor levels by limiting MID1, a novel translation enhancer and promoter of oncogenic signaling.
    Köhler A; Demir U; Kickstein E; Krauss S; Aigner J; Aranda-Orgillés B; Karagiannidis AI; Achmüller C; Bu H; Wunderlich A; Schweiger MR; Schaefer G; Schweiger S; Klocker H; Schneider R
    Mol Cancer; 2014 Jun; 13():146. PubMed ID: 24913494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MAPK4 promotes prostate cancer by concerted activation of androgen receptor and AKT.
    Shen T; Wang W; Zhou W; Coleman I; Cai Q; Dong B; Ittmann MM; Creighton CJ; Bian Y; Meng Y; Rowley DR; Nelson PS; Moore DD; Yang F
    J Clin Invest; 2021 Feb; 131(4):. PubMed ID: 33586682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel AR translational regulator lncRNA LBCS inhibits castration resistance of prostate cancer.
    Gu P; Chen X; Xie R; Xie W; Huang L; Dong W; Han J; Liu X; Shen J; Huang J; Lin T
    Mol Cancer; 2019 Jun; 18(1):109. PubMed ID: 31221168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MYBL2 disrupts the Hippo-YAP pathway and confers castration resistance and metastatic potential in prostate cancer.
    Li Q; Wang M; Hu Y; Zhao E; Li J; Ren L; Wang M; Xu Y; Liang Q; Zhang D; Lai Y; Liu S; Peng X; Zhu C; Ye L
    Theranostics; 2021; 11(12):5794-5812. PubMed ID: 33897882
    [No Abstract]   [Full Text] [Related]  

  • 9. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
    Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
    Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Genome-Wide CRISPR Activation Screen Identifies PRRX2 as a Regulator of Enzalutamide Resistance in Prostate Cancer.
    Rodríguez Y; Unno K; Truica MI; Chalmers ZR; Yoo YA; Vatapalli R; Sagar V; Yu J; Lysy B; Hussain M; Han H; Abdulkadir SA
    Cancer Res; 2022 Jun; 82(11):2110-2123. PubMed ID: 35405009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting GRP78-dependent AR-V7 protein degradation overcomes castration-resistance in prostate cancer therapy.
    Liao Y; Liu Y; Xia X; Shao Z; Huang C; He J; Jiang L; Tang D; Liu J; Huang H
    Theranostics; 2020; 10(8):3366-3381. PubMed ID: 32206096
    [No Abstract]   [Full Text] [Related]  

  • 12. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.
    Karantanos T; Evans CP; Tombal B; Thompson TC; Montironi R; Isaacs WB
    Eur Urol; 2015 Mar; 67(3):470-9. PubMed ID: 25306226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer-associated fibroblasts promote prostate tumor growth and progression through upregulation of cholesterol and steroid biosynthesis.
    Neuwirt H; Bouchal J; Kharaishvili G; Ploner C; Jöhrer K; Pitterl F; Weber A; Klocker H; Eder IE
    Cell Commun Signal; 2020 Jan; 18(1):11. PubMed ID: 31980029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcription of Nrdp1 by the androgen receptor is regulated by nuclear filamin A in prostate cancer.
    Savoy RM; Chen L; Siddiqui S; Melgoza FU; Durbin-Johnson B; Drake C; Jathal MK; Bose S; Steele TM; Mooso BA; D'Abronzo LS; Fry WH; Carraway KL; Mudryj M; Ghosh PM
    Endocr Relat Cancer; 2015 Jun; 22(3):369-86. PubMed ID: 25759396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteostasis by STUB1/HSP70 complex controls sensitivity to androgen receptor targeted therapy in advanced prostate cancer.
    Liu C; Lou W; Yang JC; Liu L; Armstrong CM; Lombard AP; Zhao R; Noel ODV; Tepper CG; Chen HW; Dall'Era M; Evans CP; Gao AC
    Nat Commun; 2018 Nov; 9(1):4700. PubMed ID: 30446660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implications of ubiquitin ligases in castration-resistant prostate cancer.
    Qi J; Fan L; Hussain A
    Curr Opin Oncol; 2015 May; 27(3):172-6. PubMed ID: 25811345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of microRNA-21 expression with clinicopathological characteristics and the risk of progression in advanced prostate cancer patients receiving androgen deprivation therapy.
    Guan Y; Wu Y; Liu Y; Ni J; Nong S
    Prostate; 2016 Aug; 76(11):986-93. PubMed ID: 27040772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA; Yen AE; Weigel NL
    Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-30a inhibits androgen-independent growth of prostate cancer via targeting MYBL2, FOXD1, and SOX4.
    Li X; Jiao M; Hu J; Qi M; Zhang J; Zhao M; Liu H; Xiong X; Dong X; Han B
    Prostate; 2020 Jun; 80(9):674-686. PubMed ID: 32294305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nrdp1-mediated regulation of ErbB3 expression by the androgen receptor in androgen-dependent but not castrate-resistant prostate cancer cells.
    Chen L; Siddiqui S; Bose S; Mooso B; Asuncion A; Bedolla RG; Vinall R; Tepper CG; Gandour-Edwards R; Shi X; Lu XH; Siddiqui J; Chinnaiyan AM; Mehra R; Devere White RW; Carraway KL; Ghosh PM
    Cancer Res; 2010 Jul; 70(14):5994-6003. PubMed ID: 20587519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.